Kuros Biosciences AG Stock Swiss Exchange
Stocks
CH0325814116
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 738M 912M 784M 673M 1.26B 86.23B 1.26B 8.74B 3.38B 44.16B 3.42B 3.35B 141B | P/E 2026 * |
90.1x | P/E 2027 * | 38.6x |
|---|---|---|---|---|---|
| Enterprise Value | 727M 899M 773M 663M 1.24B 84.98B 1.24B 8.62B 3.33B 43.52B 3.37B 3.3B 139B | EV / Sales 2026 * |
4.36x | EV / Sales 2027 * | 3.11x |
| Free-Float |
68.55% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Kuros Biosciences AG
| 1 day | +0.42% |
| Manager | Title | Age | Since |
|---|---|---|---|
Christopher Fair
CEO | Chief Executive Officer | 56 | 2023-10-11 |
Joost de Bruijn
CEO | Chief Executive Officer | 60 | 2017-12-03 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 2023-02-16 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 2018-06-13 | |
Joost de Bruijn
BRD | Director/Board Member | 60 | 2018-06-13 |
Oliver Walker
BRD | Director/Board Member | 57 | 2018-06-13 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.42% | +0.42% | - | - | 912M | |
| -0.38% | -0.99% | +42.69% | +100.85% | 67.82B | |
| -2.71% | -0.71% | +35.89% | +81.43% | 63.22B | |
| -0.31% | +3.67% | -12.96% | +374.95% | 27.58B | |
| +0.86% | +2.12% | -7.74% | -13.34% | 26.06B | |
| +1.11% | -0.89% | +25.81% | +14.85% | 25.38B | |
| -1.11% | +0.90% | +22.24% | -18.50% | 19.89B | |
| +1.15% | -5.02% | +219.82% | +379.02% | 17.4B | |
| +0.65% | +0.41% | -6.59% | +529.71% | 14.95B | |
| -0.20% | +8.00% | +55.78% | +167.98% | 14.62B | |
| Average | -0.08% | +1.67% | +41.66% | +179.66% | 30.77B | |
| Weighted average by Cap. | -0.55% | +0.90% | +36.99% | +140.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 167M 206M 177M 152M 284M 19.48B 285M 1.98B 764M 9.98B 774M 757M 31.78B | 224M 276M 238M 204M 382M 26.14B 383M 2.65B 1.02B 13.39B 1.04B 1.02B 42.65B |
| Net income | 9.32M 11.52M 9.91M 8.51M 15.91M 1.09B 15.97M 111M 42.72M 558M 43.28M 42.33M 1.78B | 21.65M 26.77M 23.02M 19.76M 36.96M 2.53B 37.08M 257M 99.23M 1.3B 101M 98.32M 4.13B |
| Net Debt | -10.7M -13.22M -11.37M -9.76M -18.26M -1.25B -18.32M -127M -49.02M -640M -49.66M -48.57M -2.04B | -41.26M -51M -43.86M -37.66M -70.43M -4.82B -70.66M -489M -189M -2.47B -192M -187M -7.87B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
